IL-17E, a proinflammatory cytokine, has antitumor efficacy against several tumor types in vivo

@article{Benatar2009IL17EAP,
  title={IL-17E, a proinflammatory cytokine, has antitumor efficacy against several tumor types in vivo},
  author={T. Benatar and M. Cao and Yoon Lee and J. Lightfoot and Ningping Feng and X. Gu and V. Lee and Hongnan Jin and M. Wang and Jim A. Wright and A. Young},
  journal={Cancer Immunology, Immunotherapy},
  year={2009},
  volume={59},
  pages={805-817}
}
Interleukin-17E (IL-17E) belongs to a novel family of cytokines that possess significant homology to IL-17. IL-17E has potent inflammatory effects in vitro and in vivo. Overexpression of IL-17E in mice results in a T helper-2 (Th2)-type immune response, which includes the expansion of eosinophils through the production of IL-5, and elevated gene expression of IL-4 and IL-13 in multiple tissues. In this study, we show that IL-17E has antitumor activity in vivo, a previously unrecognized function… Expand
Therapeutic Gene Therapy for Cancer with Interleukin-23
TLDR
It is demonstrated that injection of an adenovirus expressing IL-23 into the tumor microenvironment results in significantly enhanced survival and tumor rejection in 40 percent of animals, with concomitant induction of protective anti-tumor immunity, and it is shown thatIL-23 does possess therapeutic anti-Tumor effects, but does not synergize with IL-12 to enhance tumor eradication. Expand
Role of IL-17 and IL-17 Family Cytokines on Tumor Development
TLDR
The latest findings on the functions of IL-17 family members in cancer and the potential of these molecules as therapeutic targets are reviewed. Expand
IL-17A and its homologs IL-25/IL-17E recruit the c-RAF/S6 kinase pathway and the generation of pro-oncogenic LMW-E in breast cancer cells
TLDR
It is reported that IL-17A andIL-17E receptors subunits mRNA expressions are upregulated in breast cancers versus normal samples, and some of the molecular pathways activated by IL- 17A and IL-18E that may participate to their pro-oncogenic activity in breast cancer patients are shown for the first time. Expand
Cisplatin inhibits the growth, migration and invasion of cervical cancer cells by down-regulating IL-17E/IL-17RB.
TLDR
Cisplatin inhibits the viability, migration, invasion, and promotes the apoptosis of cervical cancer cells possibly by down-regulating IL-17E/17RB signaling, and may be the first choice for cervical cancer patients with abnormally high IL- 17E expression. Expand
Targeting the Tumor Microenvironment: The Protumor Effects of IL-17 Related to Cancer Type
TLDR
This knowledge calls upon further in vitro and in vivo studies that would allow the development and implementation of novel strategies to combat tumors, as well as underscoring the IL-17/IL-17R axis as promising immunotherapeutic target in the context of cancer managing. Expand
Tumor-infiltrating macrophages express interleukin-25 and predict a favorable prognosis in patients with gastric cancer after radical resection
TLDR
The results suggest that IL-25+IT cells may be a novel therapeutic target in patients with GC after radical resection, and positively associated with histological grade and found to be an independent predictor of favorable survival in patientswith GC afterradical resection. Expand
Functional specialization of interleukin-17 family members.
TLDR
The identified functions of each IL-17 family member are described and the potential of these molecules as therapeutic targets are discussed. Expand
Much More Than IL-17A: Cytokines of the IL-17 Family Between Microbiota and Cancer
TLDR
The role of the other cytokines of the IL-17 family in the interplay between microbiota and epithelial cells that may contribute to cancer pathogenesis and immune surveillance is focused on. Expand
Interleukin-17 Could Promote Breast Cancer Progression at Several Stages of the Disease
TLDR
Current literature on the pathogenic mechanisms driven by IL-17 during breast cancer progression and connections to metastasis are reviewed and it is hypothesized that these contradictory roles may be due to chronic, imbalanced versus acute transient nature of the immune reactions, as well as differences in the cells that interact with IL- 17+ cells under different circumstances. Expand
IL-17 in pancreatic disease: pathogenesis and pharmacotherapy.
TLDR
The current understanding of the pathogenesis of IL-17 in pancreatitis, type 1 diabetes mellitus (T1DM), and PC, as well as potential pharmacotherapy targeting IL- 17 and its receptors in pancreatic diseases are reviewed. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 50 REFERENCES
Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism.
TLDR
IL-17, like other cytokines, appears to be a pleiotropic cytokine with possible protumor or antitumor effects on tumor development, which often depends on the immunogenicity of tumor models. Expand
Forced Expression of Murine IL-17E Induces Growth Retardation, Jaundice, a Th2-Biased Response, and Multiorgan Inflammation in Mice
TLDR
Findings suggest that IL-17E is a unique pleiotropic cytokine and may be an important mediator of inflammatory and immune responses. Expand
Virulizin® induces production of IL-17E to enhance antitumor activity by recruitment of eosinophils into tumors
TLDR
Results support another antitumor mechanism mediated by Virulizin®, through induction of IL-17E by B cells, leading to recruitment of eosinophils into tumors, which may function in parallel with macrophages and NK cells in mediating tumor destruction. Expand
Endogenous IL-17 contributes to reduced tumor growth and metastasis.
TLDR
It is shown that tumor growth and lung metastasis were enhanced in IL-17-deficient mice, associated with decreased interferon-gamma(+) natural killer cells and tumor specific T cells in the tumor draining lymph nodes and tumors. Expand
New IL-17 Family Members Promote Th1 or Th2 Responses in the Lung: In Vivo Function of the Novel Cytokine IL-251
TLDR
The existence of a previously unrecognized cell population that may initiate Th2-like responses by responding to IL-25 in vivo is suggested and it is suggested thatIL-25 may be an important mediator of allergic disease via production of IL-4,IL-5, IL-13, and eotaxin. Expand
IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo.
TLDR
The results suggest that IL-25, derived from Th2 T cells, is capable of amplifying allergic type inflammatory responses by its actions on other cell types. Expand
Identification of Functional Roles for Both IL-17RB and IL-17RA in Mediating IL-25-Induced Activities
TLDR
It is demonstrated for the first time that IL-25-mediated activities require both IL-17RB andIL-17RA and provide another example of an IL- 17 family ligand that utilizes a heteromeric receptor complex. Expand
IL-25 regulates Th17 function in autoimmune inflammation
TLDR
It is shown that IL-25 also regulates the development of autoimmune inflammation mediated by IL-17–producing T cells, and plays opposing roles in the pathogenesis of organ-specific autoimmunity. Expand
IL-17E, a Novel Proinflammatory Ligand for the IL-17 Receptor Homolog IL-17Rh1*
  • James Lee, W. Ho, +8 authors A. Gurney
  • Medicine, Biology
  • The Journal of Biological Chemistry
  • 2001
We report identification of interleukin (IL)-17E, a novel member of the IL-17 family of cytokines. IL-17E is a ligand for the recently identified protein termed EVI27/IL-17BR, which we term IL-17Expand
Transgenic overexpression of human IL-17E results in eosinophilia, B-lymphocyte hyperplasia, and altered antibody production.
TLDR
The fact that hIL-17E overexpression results in high levels of circulating eosinophils, IL-4,IL-5, eotaxin, and IgE suggests that IL- 17E may be a proinflammatory cytokine favoring Th2-type immune responses. Expand
...
1
2
3
4
5
...